文献速递肝病

失代偿期肝硬化患者有效白蛋白的测定及其临床与预后意义

Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.
PubMed 文献 · Hepatology · 2021-05-26

该观察性研究纳入319例因急性失代偿住院的肝硬化患者(含或不含慢加急性肝衰竭)及18例年龄性别可比的代偿期门诊患者,通过液相色谱/电喷雾电离/质谱结合标准方法估算有效白蛋白浓度(eAlb),并与总白蛋白浓度(tAlb)比较。结果显示eAlb随肝硬化恶化逐步下降,在区分代偿期、急性失代偿和慢加急性肝衰竭及有无并发症方面优于tAlb,且eAlb而非tAlb与ACLF中的结合能力密切相关;入院时eAlb比tAlb更好地预测30天内ACLF发生和90天死亡率。

要点

  • eAlb可量化并与常规tAlb区分,与疾病严重程度和白蛋白功能障碍更相关。
  • eAlb在区分代偿期、急性失代偿和ACLF及有无并发症方面优于tAlb。
  • 入院时eAlb比tAlb更好地预测30天内ACLF发生和90天死亡率。

核心结论

  • 在失代偿期肝硬化患者中,eAlb可被量化并与临床常规测量的tAlb区分,且比tAlb更密切关联疾病严重程度和白蛋白功能障碍,具有更强的预后价值。

研究设计与样本

  • 观察性研究纳入319例因急性失代偿住院的肝硬化患者(含或不含ACLF)和18例年龄与性别可比的代偿期肝硬化门诊患者。
  • tAlb通过标准方法定量,eAlb通过液相色谱/电喷雾电离/质谱结合标准方法估算,白蛋白结合与解毒效率通过电子顺磁共振分析评估。

主要发现

  • 失代偿期肝硬化患者循环白蛋白显示多种结构异常,以可逆性氧化和糖基化最常见。
  • eAlb随肝硬化恶化逐步下降,在区分代偿期肝硬化、急性失代偿和ACLF以及有无并发症患者方面优于tAlb。
  • 在ACLF中,eAlb而非tAlb与结合能力密切相关。
  • 入院时eAlb比tAlb更好地预测30天内ACLF发生和90天死亡率。

临床怎么用

  • eAlb可作为比tAlb更紧密关联疾病严重程度和白蛋白功能障碍的指标,并具有更强预后预测能力。
  • 研究结果提示未来可评估eAlb作为预测预后和治疗反应的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Circulating albumin in cirrhosis can be dysfunctional because of accumulating structural damages, leading to the concept of effective albumin concentration (eAlb), referring to the albumin portion presenting structural and functional integrity. We aimed to estimate eAlb in patients with decompensated cirrhosis and analyze its relationships with albumin function and clinical outcomes as compared to total albumin concentration (tAlb). APPROACH AND RESULTS: We evaluated 319 patients with cirrhosis hospitalized for acute decompensation (AD) with and without acute-on-chronic liver failure (ACLF) and 18 age- and sex-comparable outpatients with compensated cirrhosis. tAlb was quantified by standard assay, whereas eAlb was estimated combining liquid chromatography/electrospray ionization/mass spectrometry and standard methods. Albumin binding and detoxification efficiency were evaluated by electron paramagnetic resonance analysis. Circulating albumin in patients with decompensated cirrhosis displayed multiple structural abnormalities, with reversible oxidation and glycation being the most frequent. As a result, eAlb progressively declined with the worsening of cirrhosis and was superior to tAlb in stratifying patients between compensated cirrhosis, AD, and ACLF, as well as patients with and without complications. Moreover, eAlb, but not tAlb, was closely associated with binding capacities in ACLF. Finally, eAlb at admission predicted the occurrence of ACLF within 30 days and mortality at 90 days better than tAlb. CONCLUSIONS: This large, observational study provides the evidence in patients with decompensated cirrhosis that eAlb can be quantified and differentiated from tAlb routinely measured in clinical practice. As compared to tAlb, eAlb is more closely associated with disease severity and albumin dysfunction and carries a greater prognostic power. These results prompt future research assessing eAlb as a biomarker for predicting prognosis and treatment response.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Baldassarre M, Naldi M, Zaccherini G, et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology. 2021. PMID: 33710623. doi:10.1002/hep.31798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。